Eli Lilly’s outstanding quarter should calm concerns about the stock

Eli Lilly on Thursday reported a successful quarter driven by sales of its blockbuster obesity and diabetes drugs, allaying any lingering investor concerns about the stock. Second-quarter revenue rose 36% year-over-year to $11.3 billion, beating expectations of $9.92 billion, according…